<DOC>
	<DOC>NCT02247154</DOC>
	<brief_summary>To determine: 1. The safety of Vigam® Liquid in patients with primary or secondary antibody deficiency (PAD or SAD). 2. The efficacy of Vigam® Liquid in patients with primary or secondary antibody deficiency. 3. The half-life of Vigam® Liquid after 4 months of treatment. 4. The subclass and total gammaglobulin concentrations after each infusion of Vigam® Liquid.</brief_summary>
	<brief_title>A Study of the Safety and Efficacy of Vigam® Liquid in Patients With Primary or Secondary Antibody Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Adults (1880 years) with PAD or SAD With a low serum IgG (&lt;6 g/l) and a history of recurrent infections Requiring and eligible for polyvalent intravenous immunoglobulin (IVIG) replacement therapy Nonreactive for HBsAg and with an alanine aminotransferase (ALT) level less than twice upper limit of normal prior to entry into the trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>